Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „Approximately“
Suchtreffer
Begriffe & Kennungen
Aclasta · 4.8 · Hypocalcaemia In clinical trials in osteoporosis, approximately 0.2% of patients had notable declines of serum
Eintrag öffnenAclasta · 4.8 · In the Paget’s disease trials, symptomatic hypocalcaemia was observed in approximately 1% of patients, in all
Eintrag öffnenAdjupanrix (previously Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals) · 4.8 · Clinical studies have evaluated the incidence of adverse reactions listed below in approximately 5 000 subject
Eintrag öffnenAdjupanrix (previously Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals) · 4.8 · Three clinical studies evaluated the incidence of adverse reactions in approximately 437 children aged 6 month
Eintrag öffnenAdjupanrix (previously Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals) · 4.8 · Two clinical studies evaluated the incidence of adverse reactions in approximately 824 children aged 3 to < 18
Eintrag öffnenAkynzeo · 4.5 · Erythromycin and Midazolam Exposure to erythromycin and midazolam was increased approximately 1.3 and 2.4 fold
Eintrag öffnenAkynzeo · 4.5 · Erythromycin and Midazolam Exposure to erythromycin and midazolam was increased approximately 1.3 and 2.4 fold
Eintrag öffnenAkynzeo · 4.5 · Erythromycin and midazolam Exposure to erythromycin and midazolam was increased approximately 1.3 and 2.4 fold
Eintrag öffnenAkynzeo · 4.5 · Erythromycin and midazolam Exposure to erythromycin and midazolam was increased approximately 1.3 and 2.4 fold
Eintrag öffnenAvastin · 4.8 · Fatal outcome was reported in approximately a third of serious cases of gastrointestinal perforations, which r
Eintrag öffnenAzopt · 4.8 · In small short-term clinical trials, approximately 12.5% of paediatric patients were observed to experience ad
Eintrag öffnenBimzelx · 4.8 · Approximately 31% of patients with psoriatic arthritis treated with bimekizumab at the recommended dosing regi
Eintrag öffnenBimzelx · 4.8 · Approximately 44% of patients with AS treated with bimekizumab up to 52 weeks at the recommended dosing regime
Eintrag öffnenBimzelx · 4.8 · Approximately 45% of plaque psoriasis patients treated with bimekizumab up to 56 weeks at the recommended dosi
Eintrag öffnenBimzelx · 4.8 · Approximately 57% of patients with nr-axSpA treated with bimekizumab up to 52 weeks at the recommended dosing
Eintrag öffnenBimzelx · 4.8 · Approximately 59% of HS patients treated with bimekizumab up to 48 weeks at the recommended dosing regimen (32
Eintrag öffnenBiopoin · 4.8 · Summary of the safety profile Approximately 9% of patients can be expected to experience an adverse reaction.
Eintrag öffnenBondronat · 4.5 · Bioavailability was reduced by approximately 75% when Bondronat tablets were administered 2 hours after a stan
Eintrag öffnenBrilique · 4.5 · Rosuvastatin (BCRP substrate) Ticagrelor has been shown to increase rosuvastatin Cmax by approximately 2.5-fol
Eintrag öffnenBrilique · 4.5 · Rosuvastatin (BCRP substrate) Ticagrelor has been shown to increase rosuvastatin Cmax by approximately 2.5-fol
Eintrag öffnen